Stay updated with breaking news from Neil Kumar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BridgeBio's shot at entering a competitive market for a rare heart condition narrowed Monday after a "baffling" result in a phase 3 clinical trial where placebo patients bested those who received the treatment in a walk test.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BridgeBio reported its drug acoramidis missed the main goal of a pivotal study in patients with transthyretin amyloidosis affecting the heart—the same type of patients helped by a currently approved blockbuster Pfizer drug. BridgeBio attributed the trial failure to a surprisingly strong placebo response, and it will continue the study, hoping for better outcomes on additional goals.
See, earlier: Arkansas GOP, Big Tech, Try To Can...
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced...